CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 65 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Posaconazole 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02387983
NCT02387983Phase 1Completed
CompareCT.gov

Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

Merck Sharp & Dohme LLC·interventional·Posted Mar 13, 2015·Updated Oct 9, 2018

In Brief

A Phase 1 clinical trial evaluating Posaconazole for Fungal Infection. Completed, enrolled 65 participants.

Detailed Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of oral posaconazole tablets in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFungal Infection
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 13, 2015
Enrollment StartMay 6, 2015
Primary CompletionMay 2, 2016
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.3 years ago

Interventions

Posaconazoledrug

Posaconazole 300 mg solid oral tablet